Role of epigenetic mechanisms in cisplatin-induced toxicity

Autor(es)

Franca Quintanilha, Julia Coelho ^[1] ; Francinette Saavedra, Kathleen ^[2] ; Visacri, Marilia Berlofa ^[3] ; Moriel, Patricia ^{[1, 4]} ; Salazar, Luis A. ^[2]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Sch Med Sci, Campinas, SP - Brazil

^[2] Univ La Frontera, Ctr Mol Biol & Pharmacogenet, Sci & Technol Bioresource Nucleus, 01145 Francisco Salazar St, Temuco 4811230 - Chile

^[3] Fundacao Ctr Med Campinas, Campinas, SP - Brazil

^[4] Univ Estadual Campinas, Fac Pharmaceut Sci, 200 Candido Portinari St, BR-13083871 Campinas, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY; v. 137, p. 131-142, MAY 2019.
• Citações Web of Science: 1

Resumo

Cisplatin (CDDP) is a highly effective antineoplastic agent, widely used in the treatment of various malignant tumors. However, its major problems are side effects associated to toxicity. Considerable inter-individual differences have been reported for CDDP-induced toxicity due to genetic and epigenetic factors. Genetic causes are well described; however, epigenetic modifications are not fully addressed. In the last few years, many evidences were found linking microRNA to the development of CDDP-mediated toxicity, particularly nephrotoxicity. In this review, we described how genetic and epigenetic modifications can be important determinants for the development of toxicity in patients treated with CDDP, and how these alterations may be interesting biomarkers for monitoring toxicity induced by CDDP. Considering the validation in different studies, we suggest that miR-34a, -146b, -378a, -192, and -193 represent an attractive study group to evaluate potential biomarkers to detect CDDP-related nephrotoxicity. (AU)

• Processo FAPESP: 17/02338-0 - MicroRNAs e biomoléculas oxidadas como possíveis biomarcadores de nefrotoxicidade induzida pela cisplatina em pacientes com câncer de cabeça e pescoço
• Beneficiário: Júlia Coelho França Quintanilha
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 17/11329-4 - Avaliação de microRNAs circulantes, biomoléculas oxidadas e polimorfismos nos genes da CYP2E1, ABCB1 e ABCC2 como possíveis biomarcadores de toxicidades induzidas por cisplatina em pacientes com câncer de cabeça e pescoço
• Beneficiário: Patricia Moriel
• Linha de fomento: Auxílio à Pesquisa - Regular